Mutual of America Capital Management LLC Has $204,000 Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Mutual of America Capital Management LLC cut its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 14.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,330 shares of the biopharmaceutical company’s stock after selling 3,184 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Dynavax Technologies were worth $204,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Assenagon Asset Management S.A. acquired a new position in shares of Dynavax Technologies in the third quarter worth $8,291,000. Entropy Technologies LP acquired a new position in Dynavax Technologies during the third quarter worth $462,000. Millennium Management LLC acquired a new position in Dynavax Technologies during the second quarter worth $17,615,000. Vanguard Group Inc. increased its position in Dynavax Technologies by 1.4% during the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock worth $116,682,000 after buying an additional 126,458 shares during the last quarter. Finally, AlphaCentric Advisors LLC increased its position in Dynavax Technologies by 55.0% during the third quarter. AlphaCentric Advisors LLC now owns 201,500 shares of the biopharmaceutical company’s stock worth $2,245,000 after buying an additional 71,500 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Stock Down 0.4 %

DVAX stock opened at $12.86 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The company has a 50-day moving average of $11.65 and a two-hundred day moving average of $11.38. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of 98.92 and a beta of 1.34.

Analyst Ratings Changes

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group lowered their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.